AXLA · Axcella Health Inc

-

Please sign in to comment on AXLA

1 Comment

Admin

4 years ago

Axcella Health Inc is currently in a long term downtrend where the price is trading 20.3% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Axcella Health Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 3.3% to $-15M since the same quarter in the previous year.

Finally, its free cash flow grew by 23.6% to $-10M since the same quarter in the previous year.

Based on the above factors, Axcella Health Inc gets an overall score of 3/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US05454B1052
Sector	Healthcare
Industry	Biotechnology

Market Cap	1M
PE Ratio	None
Target Price	10.87
Dividend Yield	0.0%
Beta	0.57

ABOUT

Axcella Health Inc

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

AXLA · Axcella Health Inc

-

Axcella Health Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Axcella Health Inc using a moving average strategy